Cancer-related fatigue (CRF) affects between 60% and 90% of cancer patients — whether during chemotherapy, radiotherapy, or in the survivorship phase — and remains one of the most difficult-to-manage symptoms in oncology. Unlike common fatigue, CRF is rarely relieved by rest and interferes profoundly with functional capacity, social relationships, and adherence to cancer treatment. Despite the growing interest in acupuncture as a complementary intervention for this condition, the specific role of electroacupuncture — a modality that combines continuous electrical stimulation with the needles — had been little systematized to date.
A systematic review published in 2026 in Supportive Care in Cancer (Springer Nature), conducted by Campos, Minari, Alves, and colleagues, comes to fill this gap. Registered in PROSPERO, the review searched five international databases — PubMed, Embase, Virtual Health Library, Scopus, and CAPES — with no restrictions on date, language, sex, ethnicity, or cancer type. From 2,110 references identified in the initial search, five clinical trials met the inclusion criteria and were analyzed in detail. Methodologic quality was evaluated by the PEDro scale and risk of bias by RoB-2.
DIMENSIONS OF THE REVIEW
What differentiates electroacupuncture from conventional acupuncture
Electroacupuncture (EA) uses traditional needles as electrodes, applying low-frequency electrical current and variable intensity during the session. This resource allows the stimulation to be quantified and standardized — an important methodologic advantage in clinical studies — and potentiates the release of endorphins, enkephalins, and other neuromodulatory substances in the central nervous system. For cancer fatigue specifically, the hypothesis is that EA modulates the hypothalamic-pituitary-adrenal axis, reduces circulating proinflammatory cytokines (TNF-α, IL-1β, IL-6), and acts on reward circuits and sleep regulation that are frequently dysregulated in cancer patients. The review points out that, despite growing clinical interest, specific studies on EA — distinct from manual acupuncture — are still scarce, which makes this review a relevant methodologic milestone.
Results: emerging evidence, consistent clinical signal
The main quantitative finding of the review was a 2.4-point reduction in the worst fatigue score (95% CI: -2.9 to -1.9) documented in a clinical trial that evaluated EA in cancer survivors with chronic pain — the magnitude of the effect is clinically significant, considering that a difference of 1.0 point on the Brief Fatigue Inventory (BFI) is already considered relevant by specialists in supportive oncology. The other included studies reported subjective improvement in fatigue compared with control groups, with variation in the scale of instruments used. None of the five trials recorded serious adverse reactions related to EA, and mild adverse events — mild pain at the insertion site, transient ecchymosis — were infrequent. The review also identified the secondary analysis of the PEACE trial (Memorial Sloan Kettering) as one of the most robust pieces of evidence included, reinforcing the role of EA in both pain control and associated fatigue in cancer survivors.
Frequently Asked Questions
The studies included in this review did not report serious adverse reactions related to EA in patients on active cancer treatment. In general, specific care is needed in patients with severe thrombocytopenia (<50,000/mm³) — avoiding points with risk of bleeding —, intense immunosuppression, and severe peripheral neuropathy that alters local sensation. Individualized assessment by the medical acupuncturist in coordination with the oncology team is fundamental before starting treatment.
The review did not standardize the number of sessions — the included trials varied from 4 to 12 weeks of treatment. Clinically, the broader literature on acupuncture for cancer fatigue suggests that perceptible effects appear after 4 to 6 sessions, with consolidation of gains between 8 and 12 weeks. The frequency of 1 to 2 sessions per week is the most commonly used in trials. The medical acupuncturist should reassess the response periodically and adapt the duration of treatment to the patient’s oncologic context.
No — EA is a complementary intervention, not an alternative. In all studies of this review, it was used as adjunctive to standard cancer care, not as a substitute. The ideal approach is multidisciplinary: the oncologist evaluates and treats treatable causes of fatigue (anemia, hypothyroidism, depression), while the medical acupuncturist contributes EA as an additional supportive resource. Integration coordinated by the physician is the model that best serves the cancer patient.
Founded in 1989 by physicians trained at the University of São Paulo (USP) and specialized in China, CEIMEC is a Brazilian national reference in the teaching and practice of medical acupuncture. With more than 3,000 physicians trained over 35 years, it collaborates with HC-FMUSP and is recognized by the Brazilian Medical College of Acupuncture (CMBA/AMB).
Learn More about this Topic
Related educational articles
Cancer Pain: Multidisciplinary Clinical Management
Understand cancer-related pain and its treatment — mechanisms, assessment, the WHO analgesic ladder, and the role of acupuncture as an integrative therapy.
Can Cancer Patients Receive Electroacupuncture? Safety Guidelines
Indications, precautions, and contraindications for electroacupuncture in cancer patients
Chronic Fatigue: Recognize, Diagnose, and Treat
Understand myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) — a complex neuroimmunological condition, its mechanisms, diagnosis, and therapeutic approaches.